ProMIS Neurosciences Inc (PMN)

[Phoenix300]

ProMIS Neurosciences to Present at HC Wainwright Investor Conference

Company to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs

TORONTO, Ontario and CAMBRIDGE, Mass. —September 3, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC. The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link http://wsw.com/webcast/hcw5/arfxf/.